

Biotechnology UltraSector ProFund

Investor Class BIPIX



Semi-annual Shareholder Report – January 31, 2025

Fund Overview

This Semi-annual shareholder report contains important information about the Biotechnology UltraSector ProFund (the "Fund") for the period of August 1, 2024 to January 31, 2025. You can find additional information about the Fund at www.profunds.com/shareholder-reports. You can also request this information by contacting us at 888-776-3637.

What were the Fund's costs for the last six months?

(based on a hypothetical \$10,000 investment)

| Class Name | Costs of a \$10,000 investment | Costs paid as a percentage of a \$10,000 investment |
|----------------|--------------------------------|---|
| Investor Class | \$71 | 1.51% |

| Fund Statistics | |
|------------------------------|--------------|
| Net Assets | \$84,974,602 |
| Number of Holdings* | 143 |
| Net Investment Advisory Fees | \$373,513 |
| Portfolio Turnover | 23% |

* No. of Holdings excludes any derivatives and collateral for securities loaned.

| Largest Sector Weights | |
|------------------------|------|
| Sector | |
| Biotechnology | 100% |

| Market Exposure | |
|---|------------------------|
| Investment Type | % of Net Assets |
| Equity Securities | 81% |
| S&P Biotechnology Select Industry Index Swap Agreements | 70% |
| Total | 151% |

| Largest Equity Holdings | |
|-------------------------------|------------------------|
| Holding | % of Net Assets |
| Neurocrine Biosciences, Inc. | 2.2% |
| Alynham Pharmaceuticals, Inc. | 2.0% |
| Natera, Inc. | 2.0% |
| AbbVie, Inc. | 2.0% |
| Gilead Sciences, Inc. | 2.0% |

"Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and instruments used for cash management.

Biotechnology UltraSector ProFund

Investor Class BIPIX

Semi-annual Shareholder Report – January 31, 2025

Additional information about the Fund including the Financial Statements, Prospectus and Statement of Additional Information is available: On the Fund's website, www.profunds.com/shareholder-reports, or upon request, by calling 888-776-3637.

